---
title: "LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285747453.md"
description: "LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on Kodiak Sciences (KOD) with a price target of $65.00. Dolezal, a 5-star analyst with a 45.41% success rate, reports an average return of 17.4%. The consensus among analysts for Kodiak Sciences is a Strong Buy, with an average price target of $63.80."
datetime: "2026-05-08T14:56:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285747453.md)
  - [en](https://longbridge.com/en/news/285747453.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285747453.md)
---

# LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Kodiak Sciences, with a price target of $65.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Dolezal is a 5-star analyst with an average return of 17.4% and a 45.41% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Rocket Pharmaceuticals, and Kodiak Sciences.

Currently, the analyst consensus on Kodiak Sciences is a Strong Buy with an average price target of $63.80.

### Related Stocks

- [KOD.US](https://longbridge.com/en/quote/KOD.US.md)
- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News](https://longbridge.com/en/news/285606116.md)
- [Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC](https://longbridge.com/en/news/284994537.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)